obesity treatment with bariatric surgery vs glp-1 receptor agonists ESG vs. vs. Therapy: Where Do We Stand in 2025? Anti-obesity drugs are closing the

Bawa T, Dhingra V, Malhotra N, Wasir JS, Mithal A

Factors including baseline heart rate, dose level , cardiovascular fitness, and individual receptor sensitivity all influence the response

adult populationtake glucagon-like peptide-1 receptor agonists (GLP-1RAs) for chronic diseases or weight loss

Kapogiannis D, Mustapic M, Shardell MD, Berkowitz ST, Diehl TC, Spangler RD, et al

Short-acting GLP-1 receptor agonists primarily slow gastric emptying, and thus exert their main effect on postprandial blood glucose levels

Canada has recently approved a generic version of Ozempic, which could undermine Novo Nordisk's pricing power considerably